Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 13, keine Gesamtzahl für „Repaglinide“
Suchtreffer
Begriffe & Kennungen
Repaglinide Teva · 4.8 · Hypersensitivity Hypersensitivity reactions of the skin may occur as erythema, itching, rashes and urticaria.
Eintrag öffnenRepaglinide Teva · 4.8 · Immune system disorders Allergic reactions* Very rare Metabolism and nutrition Hypoglycaemia Common disorders
Eintrag öffnenRepaglinide Teva · 4.8 · Refraction disorders Changes in blood glucose levels have been known to result in transient visual disturbance
Eintrag öffnenRepaglinide Teva · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenRepaglinide Teva · 4.8 · Summary of the safety profile The most frequently reported adverse reactions are changes in blood glucose leve
Eintrag öffnenRepaglinide Teva · 4.8 · Tabulated list of adverse reactions Based on the experience with repaglinide and with other hypoglycaemic medi
Eintrag öffnenRetsevmo · 4.5 · 9 amodiaquine, cerivastatin, enzalutamide, paclitaxel, repaglinide, torasemide, sorafenib, rosiglitazone, bupr
Eintrag öffnenRetsevmo · 4.5 · Sensitive CYP2C8 substrates Selpercatinib increased the Cmax and AUC of repaglinide (a substrate of CYP2C8) by
Eintrag öffnenRetsevmo · 4.5 · Sensitive CYP2C8 substrates Selpercatinib increased the Cmax and AUC of repaglinide (a substrate of CYP2C8) by
Eintrag öffnenSkyclarys · 4.5 · CYP2C8 substrates The AUC of repaglinide, a CYP2C8 substrate, was reduced by approximately 35% when co-adminis
Eintrag öffnenTukysa · 4.5 · CYP2C8 substrates A clinical drug interaction study found that co-administration of tucatinib with repaglinide
Eintrag öffnenXenleta · 4.3 · Coadministration with sensitive CYP2C8 substrates (e.g. repaglinide) (see section 4.5).
Eintrag öffnenXenleta · 4.3 · Coadministration with sensitive CYP2C8 substrates (e.g. repaglinide) (see section 4.5).
Eintrag öffnenXenleta · 4.5 · 18 Repaglinide* Not studied Co-administration with 0.25 mg single dose Expected lefamulin may lead to ↑Repagli
Eintrag öffnenXenleta · 4.5 · Co-administration of lefamulin with medicinal products metabolised by CYP2C8 (e.g. repaglinide) may result in
Eintrag öffnenXenleta · 4.5 · Co-administration of lefamulin with sensitive CYP2C8 substrates such as repaglinide may result in increased pl
Eintrag öffnenZyllt · 4.5 · CYP2C8 substrate medicinal products: Clopidogrel has been shown to increase repaglinide exposure in healthy vo
Eintrag öffnenrepaglinide
Eintrag öffnenrepaglinide
Eintrag öffnenrepaglinide
Eintrag öffnen